/
Oncology
Locally-Advanced Rectal Cancer
64
Pipeline Programs↗
90
Active Trials↗
25
Companies Involved↗
Locally-advanced Rectal Cancer is a moderately active landscape with 64 programs across 25 companies. The most active players are Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Henlius Biotech. 20 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 16
Phase 235
Phase 320
Approved
No programs
Analysis
Modality Breakdown
74%
Small molecule
43 of 58 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 58 classified programs, each share of the total. Modality classified for 94% of 64 pipeline programs.
Analysis
Trial Status
177
clinical trials
Completed44 · 25%
Recruiting42 · 24%
Unknown status34 · 19%
Not yet recruiting26 · 15%
Active, not recruiting22 · 12%
Terminated6 · 3%
Other3 · 2%
Clinical Trials
Trial Activity
177 trials
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer
Recruiting·—·Phase 2/3·NCT06312982·375 enrolled
Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Recruiting·—·Phase 2·NCT07040098·228 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)